New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > Skin Cancer

Skin Cancer Regimens



Basal cell Regimens


Published

Name
Id
Version
Date
SKIN BCC Metastatic - vismodegib
57441000210102
3.0.0
29/06/2025

Melanoma Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
SKIN Melanoma Metastatic - [for brain metastasis] ipilimumab 3mg/kg and nivolumab 1mg/kg
57501000210101
1.0.0
02/08/2024
SKIN Melanoma Metastatic - biNIMEtinib and encorafenib
57401000210100
2.0.0
29/06/2025
SKIN Melanoma Metastatic - cARBOplatin, PACLItaxel, and beVACizumab
57451000210104
4.0.0
13/08/2023
SKIN Melanoma Metastatic - cOBIMEtinib and vemurafenib
57461000210101
2.0.0
29/06/2025
SKIN Melanoma Metastatic - daBRAFEnib and tRAMEtinib
58931000210101
2.0.0
05/07/2022
SKIN Melanoma Metastatic - dacarbazine
57471000210107
2.0.0
13/08/2023
SKIN Melanoma Metastatic - imatinib
57481000210109
3.0.0
29/06/2025
SKIN Melanoma Metastatic - ipilimumab 1mg/kg and nivolumab 3mg/kg
57491000210106
1.0.0
30/09/2021
SKIN Melanoma Metastatic - ipilimumab and pembrolizumab
57511000210104
1.0.0
30/09/2021
SKIN Melanoma Metastatic - nivolumab Q2W [flat dosing]
57521000210109
1.0.0
30/09/2021
SKIN Melanoma Metastatic - nivolumab Q2W [weight based dosing]
57531000210106
1.0.0
30/09/2021
SKIN Melanoma Metastatic - nivolumab Q4W [flat dosing]
57541000210103
1.0.0
30/09/2021
SKIN Melanoma Metastatic - pembrolizumab Q3W [flat dosing]
57551000210100
1.0.0
30/09/2021
SKIN Melanoma Metastatic - pembrolizumab Q3W [weight based dosing]
57561000210102
1.0.0
30/09/2021
SKIN Melanoma Metastatic - pembrolizumab Q6W [flat dosing]
57571000210108
2.0.0
26/02/2026
SKIN Melanoma Neoadjuvant - ipilimumab [flat dosing] Q3W and nivolumab [flat dosing] Q3W
506521000210102
1.0.0
05/08/2025
SKIN Melanoma NON-Metastatic - daBRAFEnib and tRAMEtinib
59021000210108
2.0.0
05/07/2022
SKIN Melanoma NON-Metastatic - nivolumab Q2W [flat dosing]
57581000210105
1.0.0
30/09/2021
SKIN Melanoma NON-Metastatic - nivolumab Q2W [weight based dosing]
57591000210107
1.0.0
30/09/2021
SKIN Melanoma NON-Metastatic - nivolumab Q4W [flat dosing]
57601000210102
1.0.0
30/09/2021
SKIN Melanoma NON-Metastatic - pembrolizumab Q3W [flat dosing]
57611000210100
1.0.0
30/09/2021
SKIN Melanoma NON-Metastatic - pembrolizumab Q3W [weight based dosing]
57621000210105
1.0.0
30/09/2021
SKIN Melanoma NON-Metastatic - pembrolizumab Q6W [flat dosing]
57631000210107
2.0.0
26/02/2026

Merkel cell Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
SKIN MCC Metastatic - cARBOplatin and etoposide
393211000210101
1.0.0
18/08/2024
SKIN MCC Metastatic - cARBOplatin and oral etoposide
393201000210103
1.0.0
18/08/2024
SKIN MCC Metastatic - pembrolizumab Q3W [flat dosing]
57431000210105
1.0.0
30/09/2021
SKIN MCC Metastatic - pembrolizumab Q3W [weight based dosing]
57421000210108
1.0.0
30/09/2021
SKIN MCC Metastatic - pembrolizumab Q6W [flat dosing]
57411000210103
2.0.0
26/02/2026

Squamous cell Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
SKIN SQCC Metastatic - cARBOplatin and PACLItaxel
393271000210105
1.0.0
18/08/2024
SKIN SQCC Metastatic - cemiplimab
393651000210100
1.0.0
18/09/2024
SKIN SQCC Metastatic - pembrolizumab Q3W [flat dosing]
57641000210104
1.0.0
30/09/2021
SKIN SQCC Metastatic - pembrolizumab Q3W [weight based dosing]
57651000210101
1.0.0
30/09/2021
SKIN SQCC Metastatic - pembrolizumab Q6W [flat dosing]
57661000210103
2.0.0
26/02/2026
SKIN SQCC Neoadjuvant - cemiplimab
393641000210103
1.0.0
18/09/2024